Kneel Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 24-10-2024
- Paid Up Capital ₹ 1.00 M
as on 24-10-2024
- Company Age 22 Year, 29 Days
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 37.36%
(FY 2023)
- Ebitda 97.55%
(FY 2023)
- Net Worth -0.09%
(FY 2023)
- Total Assets -0.50%
(FY 2023)
About Kneel Pharmaceuticals
The Company is engaged in the Infrastructure And Utilities Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Satyendra Sinha and Smrita Roy serve as directors at the Company.
- CIN/LLPIN
U24231DL2002PTC117781
- Company No.
117781
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kneel Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyendra Sinha  | Director | 08-Dec-2014 | Current |
| Smrita Roy | Additional Director | 13-Feb-2024 | Current |
Financial Performance of Kneel Pharmaceuticals.
Kneel Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 37.36% increase in profit. The company's net worth dipped by a decrease of 0.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kneel Pharmaceuticals?
In 2023, Kneel Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Ass Buildwell Private LimitedActive 19 years 11 months
Satyendra Sinha and Smrita Roy are mutual person
- I B S Exports Private LimitedActive 22 years 29 days
Satyendra Sinha and Smrita Roy are mutual person
- Sevenseas Holidays Private LimitedActive 25 years 11 months
Satyendra Sinha and Smrita Roy are mutual person
- Pusa Consultants Private LimitedActive 11 years 9 months
Satyendra Sinha and Smrita Roy are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kneel Pharmaceuticals?
Unlock and access historical data on people associated with Kneel Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kneel Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kneel Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
